Articles les plus consultés
-
francis 13 Version sans publicité Marchés Actualités Analyses Crypto Fonds Graphiques Technique Brokers Outils Portefe...
-
6% Hydroxyethyl Starch 130 / 0.4 in 0.9% Injection de chlorure de sodium (Voluven 500 mL freeflex flexible en plastique intraveineuse solut...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Iridium 14.95 + 39.07% 0,60K Mondialisation de l'Inde. 0,4800 + 18,52% 1,80K...
-
Top Gaining Stocks % Chg Dernier Symb Compagnie Le volume 16,22% 2.15 SRNE Sorrento Therapeut 7030 10,92% 2,64 CIE Cobalt Inte...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Oracle Corporation 51.30 + 10,73% 58.90K Staples Inc 9.25 + 6,81% 12,31K Delcat...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Delcath 0.1230 + 24,24% 196,67K Neos Therapeutics I. 10.50 +16.67% 34.36K Enpha...
-
Citoyens_Français @citoyenneFrance 8 juin Plus Attali : « Les élus n’ont plus de pouvoir et voici votre avenir » - Effr......
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Lipocine In 5.32 + 32,34% 38.64K Enphase Energy Inc 0,938 + 17,57% 10,37K Delca...
-
28 juin 2017 Nom du médicament et numéro de demande Ingrédient actif Formulaire de posologie / itinéraire Soumission Compagnie ...
-
Plus fortes hausses en préouverture Nom Dernier Var.% Vol. DragonWave Inc 1,3900 +25,23% 3,55K Alibaba 139,95 +11,35% 1,40M MoSys...
mardi 3 juillet 2018
Globus Medical Adds Two Innovative Solutions to Growing Trauma Portfolio
Globus Medical Adds Two Innovative Solutions to Growing Trauma Portfolio: Introducing ANTHEM® Ankle Fracture and Proximal Humerus Plate Systems
Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346 | Business Wire
Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346 | Business Wire: ANTIBE THERAPEUTICS RELEASES SECONDARY ENDPOINT DATA FROM RECENT PHASE 2B GASTROINTESTINAL SAFETY STUDY FOR LEAD DRUG, ATB-346
Poxel Announces Completion of Patient Enrollment for TIMES 1 Trial in the Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan | Business Wire
Poxel Announces Completion of Patient Enrollment for TIMES 1 Trial in the Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan | Business Wire: POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic diseases, in
dimanche 1 juillet 2018
Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results | Business Wire
Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results | Business Wire: ANTIBE THERAPEUTICS REPORTS 2018 YEAR-END FINANCIAL AND OPERATING RESULTS
Alteogen and Lynkogen Enter into an Exclusive Option Agreement to Develop Proprietary Fusion Proteins for the Treatment of NASH and Metabolic Diseases | Business Wire
Alteogen and Lynkogen Enter into an Exclusive Option Agreement to Develop Proprietary Fusion Proteins for the Treatment of NASH and Metabolic Diseases | Business Wire: Alteogen and Lynkogen enter into an exclusive option agreement to develop proprietary fusion proteins for the treatment of NASH and metabolic diseases
Inscription à :
Articles (Atom)